AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 92 min read$ABEO

Seshadri Vishwas sold $473K of ABEO

Seshadri Vishwas (Chief Executive Officer) sold 67,971 shares of ABEONA THERAPEUTICS INC. (ABEO) at $6.96 ($0.47M total) on 2026-07-09.

Original reporting
SEC EDGAR · Seshadri Vishwas
Published Jul 9, 2026, 11:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 9, 2026, 11:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ABEO
Neutral
medium confidence
Mentioned
$ABEO
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABEONeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale of 67,971 shares at $6.9637 on 2026-07-09, totaling $473,329.65.

02

Market read

Traders may monitor ABEO for additional insider activity, but the filing alone does not provide new operational or financial guidance.

03

What to watch

No 10b5-1 plan is mentioned, but the article also provides no context on prior sales, option exercises, tax events, or planned future transactions.

Relevance 4/10Novelty 5/10Timing: Filed 2026-07-09 after-hours (Form 4 timestamp 19:22:41-04:00).

Background

This is an SEC Form 4 insider transaction disclosure for ABEONA THERAPEUTICS INC. (ABEO).

Company-level read

Ticker impact

$ABEONeutralMedium confidence
Context

ABEO CEO Seshadri Vishwas sold 67,971 shares in an open-market transaction for about $473K, per a same-day Form 4 filing.

Expected impact

Likely limited, short-lived impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

The filing is a routine insider sale with no 10b5-1 plan stated and no accompanying company-specific operational update in the text.

Market effects

Sector

Minimal, as this is company-specific insider activity with no sector-wide catalyst described.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be for diversification or liquidity needs and may not signal reduced confidence, especially without evidence of a broader pattern.

Key entities

  • issuer
    ABEO

    Abeona Therapeutics Inc., the company whose CEO insider sale is disclosed.

  • insider
    Seshadri Vishwas

    Chief Executive Officer and director reporting the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABEO insider trading history →

Related articles

AUG 13
$ABEOMed

Abeona Therapeutics Swings To Q2 Net Loss; Shares Plunge

Abeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.

rttnews.com4 min
AUG 13
$ABEOMedAI 8/10

Why is Abeona Therapeutics stock slumping today?

Abeona Therapeutics (ABEO) shares fell 15.8% pre-open after it reported Q2 2026 results. The company posted a loss of 35 cents per share versus a year-earlier profit of $1.71, and revenue of $11.4M versus an estimated $12.2M. Revenue recognition for ZEVASKYN was limited by a manufacturing batch yield shortfall.

investing.com4 min
AUG 13
$ABEOMed

ABEONA THERAPEUTICS INC. (ABEO): Results of Operations and Financial Condition

ABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Abeona Therapeutics ® Reports Second Quarter 2026 Results and Provides Business Update - Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since lau

SEC EDGAR 8-K4 min
AUG 4
$ABEOMedAI 8/10

A new CMS payment could help Medicare patients access ZEVASKYN

Abeona Therapeutics (Nasdaq: ABEO) said CMS granted ZEVASKYN (prademagene zamikeracel) NTAP status under the FY2027 Hospital Inpatient Prospective Payment System rule. Abeona said NTAP adds supplemental Medicare reimbursement for technologies showing substantial clinical improvement. The company also reiterated ZEVASKYN’s safety risks, including potential cancer risk and serious allergic reactions.

stocktitan.net4 min